Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a clinical-stage oncology company advancing late-stage development of azenosertib, a first-in-class WEE1 inhibitor being developed as a biomarker-driven treatment for Cyclin E1-positive platinum-resistant ovarian cancer. The company is presenting overall survival data from the DENALI Part 1b study at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23) and the trial-in-progress poster for the Phase 3 ASPENOVA study (October 26). Zentalis reported full-year 2025 financial results and operational updates with a defined pivotal-study dose (400mg QD 5:2) selected for Cyclin E1-positive platinum-resistant ovarian cancer.